Saudi Surgeon Honored for Performing World’s First Fully Robotic Heart Transplanthttps://english.aawsat.com/varieties/5074407-saudi-surgeon-honored-performing-world%E2%80%99s-first-fully-robotic-heart-transplant
Saudi Surgeon Honored for Performing World’s First Fully Robotic Heart Transplant
Head of Cardiac Surgery and Director of the Robotics and Minimally Invasive Surgery Program at the King Faisal Specialist Hospital & Research Centre (KFSHRC) Professor Feras Khaliel - SPA
Saudi Surgeon Honored for Performing World’s First Fully Robotic Heart Transplant
Head of Cardiac Surgery and Director of the Robotics and Minimally Invasive Surgery Program at the King Faisal Specialist Hospital & Research Centre (KFSHRC) Professor Feras Khaliel - SPA
Head of Cardiac Surgery and Director of the Robotics and Minimally Invasive Surgery Program at the King Faisal Specialist Hospital & Research Centre (KFSHRC) Professor Feras Khaliel was honored at the inaugural day of the Global Health Exhibition (GHE) with the Health Research Excellence: Applied Innovation Award in recognition for his exceptional contributions to advancing research, enhancing knowledge, and fostering innovation in healthcare.
The award also commemorates Khaliel's successful completion of the world’s first robotic heart transplant on a 16-year-old patient suffering from end-stage (Class IV) heart failure, SPA reported.
According to a KFSHRC press release, the center continues to set itself apart by providing innovative specialized healthcare services, particularly through its robotic heart surgery program that has experienced accelerated success since its establishment in 2019.
In its first year, the program performed 105 robotic heart surgeries, rising to 400 and culminating in its leadership in conducting the world’s first fully robotic heart transplant, a pioneering achievement that not only bolsters Saudi Arabia's standing in healthcare but also highlights KFSHRC’s ability to innovate medical practices that enhance treatment outcomes and patient experience.
KFSHRC’s robotic heart surgery program has introduced innovative cardiac procedures, such as robotic multi-valve surgeries and robotic aortic valve replacement. Additionally, it has integrated cutting-edge technologies related to mechanical circulatory support (MCS) systems, including ventricular assist devices (VADs), which aid the heart in pumping blood. These devices serve as either a bridge to heart transplantation or a permanent solution for patients who are not eligible for transplants. This has resulted in significantly improved patient outcomes with survival rates of up to 98%, recovery times reduced by 30%, and a reduction in blood transfusions, mechanical ventilation, and hospital stay by over 50% while cutting costs by 40% compared to traditional methods.
The program is renowned for performing robotic surgeries on a wide age range of patients, from 14 to 78 years old, and for its ability to handle complex, high-risk cases, including patients with severe obesity and those requiring repeat surgeries. Notably, the program excels in performing robotic surgeries on heart patients who have undergone three previous operations, a feat in which the KFSHRC has surpassed its counterparts in American hospitals.
5 Things We Know and Still Don’t Know about COVID, 5 Years after It Appearedhttps://english.aawsat.com/varieties/5097458-5-things-we-know-and-still-don%E2%80%99t-know-about-covid-5-years-after-it-appeared
A medical worker takes a swab sample from a worker of the China Star Optoelectronics Technology (CSOT) company during a round of COVID-19 tests in Wuhan in central China's Hubei province, Aug. 5, 2021. (Chinatopix via AP, File)
TT
TT
5 Things We Know and Still Don’t Know about COVID, 5 Years after It Appeared
A medical worker takes a swab sample from a worker of the China Star Optoelectronics Technology (CSOT) company during a round of COVID-19 tests in Wuhan in central China's Hubei province, Aug. 5, 2021. (Chinatopix via AP, File)
Five years ago, a cluster of people in Wuhan, China, fell sick with a virus never before seen in the world.
The germ didn't have a name, nor did the illness it would cause. It wound up setting off a pandemic that exposed deep inequities in the global health system and reshaped public opinion about how to control deadly emerging viruses.
The virus is still with us, though humanity has built up immunity through vaccinations and infections. It's less deadly than it was in the pandemic's early days and it no longer tops the list of leading causes of death. But the virus is evolving, meaning scientists must track it closely.
Where did the SARS-CoV-2 virus come from? We don’t know. Scientists think the most likely scenario is that it circulated in bats, like many coronaviruses. They think it then infected another species, probably racoon dogs, civet cats or bamboo rats, which in turn infected humans handling or butchering those animals at a market in Wuhan, where the first human cases appeared in late November 2019.
That's a known pathway for disease transmission and likely triggered the first epidemic of a similar virus, known as SARS. But this theory has not been proven for the virus that causes COVID-19. Wuhan is home to several research labs involved in collecting and studying coronaviruses, fueling debate over whether the virus instead may have leaked from one.
It's a difficult scientific puzzle to crack in the best of circumstances. The effort has been made even more challenging by political sniping around the virus' origins and by what international researchers say are moves by China to withhold evidence that could help.
The true origin of the pandemic may not be known for many years — if ever.
People attend an exhibition on the city's fight against the coronavirus in Wuhan in central China's Hubei province, Jan. 23, 2021. (AP)
How many people died from COVID-19? Probably more than 20 million. The World Health Organization has said member countries reported more than 7 million deaths from COVID-19, but the true death toll is estimated to be at least three times higher.
In the US, an average of about 900 people a week have died of COVID-19 over the past year, according to the US Centers for Disease Control and Prevention.
The coronavirus continues to affect older adults the most. Last winter in the US, people aged 75 and older accounted for about half the nation’s COVID-19 hospitalizations and in-hospital deaths, according to the CDC.
"We cannot talk about COVID in the past, since it’s still with us," WHO director Tedros Adhanom Ghebreyesus said.
What vaccines were made available? Scientists and vaccine-makers broke speed records developing COVID-19 vaccines that have saved tens of millions of lives worldwide – and were the critical step to getting life back to normal.
Less than a year after China identified the virus, health authorities in the US and Britain cleared vaccines made by Pfizer and Moderna. Years of earlier research — including Nobel-winning discoveries that were key to making the new technology work — gave a head start for so-called mRNA vaccines.
Today, there’s also a more traditional vaccine made by Novavax, and some countries have tried additional options. Rollout to poorer countries was slow but the WHO estimates more than 13 billion doses of COVID-19 vaccines have been administered globally since 2021.
The vaccines aren't perfect. They do a good job of preventing severe disease, hospitalization and death, and have proven very safe, with only rare serious side effects. But protection against milder infection begins to wane after a few months.
Like flu vaccines, COVID-19 shots must be updated regularly to match the ever-evolving virus — contributing to public frustration at the need for repeated vaccinations. Efforts to develop next-generation vaccines are underway, such as nasal vaccines that researchers hope might do a better job of blocking infection.
This undated electron microscope image made available by the US National Institutes of Health in February 2020 shows the Novel Coronavirus SARS-CoV-2, yellow, emerging from the surface of cells, pink, cultured in the lab. (NIAID-RML via AP, File)
Which variant is dominating now? Genetic changes called mutations happen as viruses make copies of themselves. And this virus has proven to be no different.
Scientists named these variants after Greek letters: alpha, beta, gamma, delta and omicron. Delta, which became dominant in the US in June 2021, raised a lot of concerns because it was twice as likely to lead to hospitalization as the first version of the virus.
Then in late November 2021, a new variant came on the scene: omicron.
"It spread very rapidly," dominating within weeks, said Dr. Wesley Long, a pathologist at Houston Methodist in Texas. "It drove a huge spike in cases compared to anything we had seen previously."
But on average, the WHO said, it caused less severe disease than delta. Scientists believe that may be partly because immunity had been building due to vaccination and infections.
"Ever since then, we just sort of keep seeing these different subvariants of omicron accumulating more different mutations," Long said. "Right now, everything seems to locked on this omicron branch of the tree."
The omicron relative now dominant in the US is called XEC, which accounted for 45% of variants circulating nationally in the two-week period ending Dec. 21, the CDC said. Existing COVID-19 medications and the latest vaccine booster should be effective against it, Long said, since "it’s really sort of a remixing of variants already circulating."
Employees disinfect streets and shops inside Istanbul's famous Grand Bazaar to prevent the spread of coronavirus. (EPA)
What do we know about long COVID? Millions of people remain in limbo with a sometimes disabling, often invisible, legacy of the pandemic called long COVID.
It can take several weeks to bounce back after a bout of COVID-19, but some people develop more persistent problems. The symptoms that last at least three months, sometimes for years, include fatigue, cognitive trouble known as "brain fog," pain and cardiovascular problems, among others.
Doctors don’t know why only some people get long COVID. It can happen even after a mild case and at any age, although rates have declined since the pandemic's early years. Studies show vaccination can lower the risk.
It also isn't clear what causes long COVID, which complicates the search for treatments. One important clue: Increasingly researchers are discovering that remnants of the coronavirus can persist in some patients’ bodies long after their initial infection, although that can’t explain all cases.
